Clinical Trials Logo

Male Pattern Hair Loss clinical trials

View clinical trials related to Male Pattern Hair Loss.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05218642 Completed - Alopecia Clinical Trials

To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia

Start date: January 31, 2022
Phase: Phase 2
Study type: Interventional

The study is a randomized, double-blind, placebo-controlled, parallel group, phase 2 study to evaluate the efficacy, safety and tolerability of KX-826 in male subjects with androgenetic alopecia.

NCT ID: NCT04435847 Completed - Clinical trials for Male Pattern Hair Loss

Safety and Efficacy of HST 001 in Male Pattern Hair Loss

Start date: May 26, 2020
Phase: Phase 1
Study type: Interventional

HST 001 (also known as hair stimulating complex [HSC]) is a mixture of growth factors secreted by human dermal fibroblasts when cultured in proprietary bioreactors which are then harvested and concentrated to specific ranges. In both preclinical studies and in previous clinical trials, HSC has been shown to be safe, with no serious adverse events reported. This protocol design is based on the completed Phase 1 study in women which used a similar investigational product (Study 16-HIS002-US; HSC660), and includes specific objective efficacy endpoints (macrophotography) to measure Target Area Hair Counts (TAHC) after three separate doses of product separated by six weeks (week 0, week 6, week 12) and comparing to placebo treated group

NCT ID: NCT02170662 Completed - Clinical trials for Androgenetic Alopecia

Topical Bimatoprost Effect on Androgen Dependent Hair Follicles

Start date: November 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effect of bimatoprost solution on scalp hair growth. Bimatoprost 0.03% ophthalmic solution is currently approved by the FDA for treatment of glaucoma (Lumiganā„¢) and for thickening of thin eyelashes (Latisseā„¢). Bimatoprost 0.03% is not approved for the treatment of scalp hair loss and its use in this study is considered investigational which means it is still being tested in research studies. Thirty-three subjects were consented and screened, 9 entered and 9 completed the study.